A new clinical study has found that the experimental drug Daraxonrasib may significantly improve survival rates for patients with advanced pancreatic cancer, offering new hope in one of the deadliest forms of cancer.
Most pancreatic cancer cases are diagnosed at an advanced stage, when the disease has already spread and surgery is no longer an option. In such cases, chemotherapy remains the primary treatment, but many patients do not survive beyond one year after diagnosis.
More than 90 percent of pancreatic cancer patients carry a genetic mutation known as KRAS, which drives rapid tumor growth. For many years, scientists believed cancers caused by this mutation were extremely difficult to treat effectively.
However, a new generation of medicines known as RAS inhibitors has emerged over the past decade. These targeted therapies are designed to block abnormal genes such as KRAS and reduce their cancer-promoting effects.
Researchers say Daraxonrasib could represent a major breakthrough by potentially doubling the chances of survival in patients with late-stage pancreatic cancer, although further studies are needed to confirm its long-term effectiveness and safety.
Experts believe the findings mark an important step forward in the development of personalized treatments for pancreatic cancer and may offer renewed hope to patients facing limited treatment options.
